Statera BioPharma Profit Margin

Statera BioPharma (STAB) currently reports a profit margin of -2829.37% as of September 2022. That compares with -6178.0% in the prior-year period — up 54.2% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Statera BioPharma's profit margin history and peer comparisons.

Statera BioPharma's profit margin increased from -6178.0% to -2829.37% — a 54.2% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Statera BioPharma's profit margin of -2829.37% is lower than the Healthcare sector average of 14.34%. That is roughly 19824.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Statera BioPharma's current -2829.37% should be judged against Healthcare norms (sector average: 14.34%) and against STAB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2829.37%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Statera BioPharma, and consider following STAB for alerts when major investors trade the stock.